Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 3
2015 5
2016 10
2017 6
2018 4
2019 5
2020 7
2021 9
2022 5
2023 14
2024 13
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Colombo N, Gadducci A, Landoni F, Lorusso D, Sabbatini R, Artioli G, Berardi R, Ceccherini R, Cecere SC, Cormio G, De Angelis C, Legge F, Lissoni A, Mammoliti S, Mangili G, Naglieri E, Petrella MC, Ricciardi GRR, Ronzino G, Salutari V, Sambataro D, Savarese A, Scandurra G, Tasca G, Tomao F, Valabrega G, Zavallone L, Pignata S. Colombo N, et al. Among authors: cecere sc. Gynecol Oncol. 2023 Aug;175:182-189. doi: 10.1016/j.ygyno.2023.05.065. Epub 2023 Jun 22. Gynecol Oncol. 2023. PMID: 37355448
Editorial: Molecular predictive pathology in gynecologic malignancies.
Malapelle U, Uccella S, Cecere SC, De Angelis C, Giampaolino P. Malapelle U, et al. Among authors: cecere sc. Front Oncol. 2023 Oct 4;13:1301768. doi: 10.3389/fonc.2023.1301768. eCollection 2023. Front Oncol. 2023. PMID: 37869093 Free PMC article. No abstract available.
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.
Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio Pérez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. Alvarez Secord A, et al. Among authors: cecere sc. Ann Oncol. 2025 Mar;36(3):321-330. doi: 10.1016/j.annonc.2024.11.011. Epub 2024 Nov 29. Ann Oncol. 2025. PMID: 39617145 Free article. Clinical Trial.
Immunotherapy in cervix cancer.
Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Valabrega G, Musacchio L, Setola SV, Piccirillo P, Califano D, Spina A, Losito S, Greggi S, Pignata S. Attademo L, et al. Among authors: cecere sc. Cancer Treat Rev. 2020 Nov;90:102088. doi: 10.1016/j.ctrv.2020.102088. Epub 2020 Aug 7. Cancer Treat Rev. 2020. PMID: 32827839 Review.
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, van Gorp T, Konner JA, Romeo Marin M, Harter P, Murphy C, Wang Y, Esteves B, Method M, Matulonis U. Coleman RL, et al. Among authors: cecere sc. Int J Gynecol Cancer. 2024 Aug 5;34(8):1119-1125. doi: 10.1136/ijgc-2024-005401. Int J Gynecol Cancer. 2024. PMID: 38858103 Free PMC article. Clinical Trial.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Among authors: cecere sc. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options.
Forte M, Cecere SC, Di Napoli M, Ventriglia J, Tambaro R, Rossetti S, Passarelli A, Casartelli C, Rauso M, Alberico G, Mignogna C, Fiore F, Setola SV, Troiani T, Pignata S, Pisano C. Forte M, et al. Among authors: cecere sc. Crit Rev Oncol Hematol. 2024 Dec;204:104533. doi: 10.1016/j.critrevonc.2024.104533. Epub 2024 Oct 22. Crit Rev Oncol Hematol. 2024. PMID: 39442900 Review.
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
Vergote I, Copeland LJ, Van Gorp T, Laenen A, Scambia G, Thaker PH, Cibula D, Colombo N, Lea J, Gonzalez-Martin A, Korach J, Sehouli J, Monk BJ, Heinzelmann-Schwarz V, Berger R, Buscema J, Lau S, Mądry R, Denys H, Pepin JT, Salutari V, Bagaméri A, Ardizzoia A, Henry S, Cecere SC, Hruda M, Iglesias DA, Manso L, Shai A, O'Malley DM; ENGOT-ov50/GOG-3029/INNOVATE-3 Study Investigators. Vergote I, et al. Among authors: cecere sc. Eur J Cancer. 2025 Mar 26;219:115306. doi: 10.1016/j.ejca.2025.115306. Epub 2025 Feb 17. Eur J Cancer. 2025. PMID: 40010134 Free article. Clinical Trial.
Treatment of recurrent epithelial ovarian cancer.
Pignata S, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Attademo L. Pignata S, et al. Among authors: cecere sc. Cancer. 2019 Dec 15;125 Suppl 24:4609-4615. doi: 10.1002/cncr.32500. Cancer. 2019. PMID: 31967680 Free article. Review.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Among authors: cecere sc. Ann Oncol. 2025 Feb;36(2):185-196. doi: 10.1016/j.annonc.2024.10.828. Epub 2024 Nov 9. Ann Oncol. 2025. PMID: 39528049 Free article. Clinical Trial.
83 results